Oppenheimer analyst Steven Lichtman downgraded Helius Medical to Perform from Outperform following the update on the FDA submission for the company’s PoNS, with the agency declining approval and more data needed for resubmission. The next key milestones include the update on U.S. pathway following another expected FDA meeting and potential approvals in Europe/Australia, he contends.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.